Technogenetics to Offer ABL's Genotyping Products in Italy

LUXEMBOURG VILLE, Luxembourg  and MILAN, Jan. 30, 2017 /PRNewswire-iReach/ -- Advanced Biological Laboratories (ABL) S.A. and Technogenetics (TGX) today announced that they entered into an exclusive distributor agreement of the DeepChek® SingleRound Assay and software product lines in Italy. The DeepChek® SingleRound Assay product line combines target-specific PCR reagents with in vitro diagnostic software, both compatible with either Sanger or Next Generation Sequencing platforms for Virology applications (like HIV, Hepatitis C, Hepatitis B first, then for HPV, CMV, Flu, Herpes and Tuberculosis).

"We are excited to expand the offering of our sequencing and genotyping solutions in Italy and help virology or microbiology laboratories involved in the monitoring of infectious diseases like HIV or viral hepatitis C through solutions which cover all the relevant targets for genotyping, drug resistance, vaccine escape or disease prognosis".

"Our intent is to spread our commercial coverage worldwide including Europe, Asia, Africa, LATAM, North America and Middle East. We are extremely pleased by the dynamic started last year with new partners in many territories and are hopeful to pursue and solidify our commercial channel network during 2017" said Dr. Chalom Sayada, CEO of ABL.

"Technogenetics is glad to be able to offer advanced molecular genotyping reagents and software in Italy which provide, when combined with our sequencing products, robust Sanger and next-generation sequencing end-to-end workflows to research and clinical settings handling viral genotyping or drug resistance testing" said Dr. Salvatore Cincotti, CEO of Technogenetics.

The agreement is effective immediately and covers a growing portfolio of applications including DeepChek® SingleRound pan-genotypic Assays for HIV (RT/PROT and INTEGRASE), HCV Genotyping (NS5B/5'UTR/CORE), HCV Drug Resistance (NS5A/NS3/NS5B) and HBV (genotyping/drug resistance/Core-PreCore)…

About ABL

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products also received CE-marking for IVD use. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions for sequencing, clinical genotyping and drug resistance analysis, including powerful fully integrated databases and analysis systems that combine standard and high-throughput Next Generation Sequencing data. ABL's DeepChek® SingleRound HIV and Hepatitis C Virus (HCV) Genotyping and Sequencing assays are the first two in its virology reagents portfolio. These are currently available for Research Use Only.

About Technogenetics

Technogenetics is an innovative company working in the immunodiagnostics and molecular genetics fields. Technogenetics acts as a point of reference in medical and scientific community, developing and providing efficient, effective, environmentally friendly diagnostic solutions and products to improve prevention, diagnosis and treatment of several conditions. Since its origin Technogenetics has developed and produced reagents for the determination of antibodies related to many infectious diseases and thanks to its specific know-how in the endocrinology and biotechnology fields, during the years has provided an increased boost to research activities and manufacturing capabilities. Technogenetics, thanks to the experience gained over the years, operates in international contexts. Technogenetics is well-known and appreciated in the diagnostic community being attentive to customers' needs and able to propose innovative solutions and avant-garde products. Technogenetics' commercial team is highly qualified and with a solid scientific background, ensuring to clients and potential customers the best support.

Media Contact:

Dr Chalom Sayada, Advanced Biological Laboratories, +35226389676, contact@ablsa.com

Dr Giovanni Babbini, Technogenetics srl, +3902262891, info@technogenetics.it

Media Contact: Chalom Sayada, Advanced Biological Laboratories (ABL) S.A., +35226389676, contact@ablsa.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Advanced Biological Laboratories



2017

Tags

Computer Software, Pharmaceuticals, New Products & Services


Need Help